id
processing priority
4
site type
0 (generic, awaiting analysis)
review version
11
html import
20 (imported)
first seen date
2024-02-03 16:11:58
expired found date
-
created at
2024-06-05 00:48:58
updated at
2025-12-28 04:23:17
length
23
crc
59957
tld
2211
nm parts
0
nm random digits
0
nm rare letters
0
is subdomain of id
-
previous id
0
replaced with id
0
related id
-
dns primary id
dns alternative id
0
lifecycle status
0 (unclassified, or currently active)
deleted subdomains
0
page imported products
0
page imported random
0
page imported parking
0
count skipped due to recent timeouts on the same server IP
0
count content received but rejected due to 11-799
0
count dns errors
0
count cert errors
0
count timeouts
0
count http 429
0
count http 404
0
count http 403
0
count http 5xx
0
next operation date
-
server bits
—
server ip
-
mp import status
20
mp rejected date
-
mp saved date
-
mp size orig
164291
mp size raw text
1881
mp inner links count
1
mp inner links status
20 (imported)
title
Perfuse Therapeutics - Developing novel therapies to reduce blindness.
description
Perfuse Therapeutics is developing a product to improve blood flow to the retina, the most metabolically demanding tissue in the human body.
site name
Perfuse Therapeutics
author
updated
2025-12-15 19:01:52
raw text
Perfuse Therapeutics - Developing novel therapies to reduce blindness. Skip to content Menu Menu Home About Us Our Approach Pipeline News Contact Menu Home About Us Our Approach Pipeline News Contact Developing novel therapies to reduce blindness. Perfuse Therapeutics is developing a product to improve blood flow to the retina, the most metabolically demanding tissue in the human body. Our goal is to reduce the incidence of blindness. Despite current standard of care, glaucoma remains to be the leading cause of blindness and diabetic retinopathy is the leading cause of blindness in the working population in the world. Leadership We have assembled a team with remarkable and proven expertise in ocular drug discovery, drug delivery/formulation and development to advance our programs. Science Our product is a first-in-class endothelin antagonist which improves ocular blood flow and thereby addresses the underlying pathology in ocular diseases...
redirect type
0 (-)
block type
0 (no issues)
detected language
1 (English)
category id
index version
2025110801
spam phrases
0
text nonlatin
0
text cyrillic
0
text characters
1487
text words
268
text unique words
137
text lines
50
text sentences
14
text paragraphs
6
text words per sentence
19
text matched phrases
6
text matched dictionaries
2
links self subdomains
0
links other subdomains
0
links other domains
0
links spam adult
0
links spam random
0
links spam expired
0
links ext activities
0
links ext ecommerce
0
links ext finance
0
links ext crypto
0
links ext booking
0
links ext news
0
links ext leaks
0
links ext ugc
1 - linkedin.com
links ext klim
0
links ext generic
0
dol status
0
dol updated
2025-12-15 19:01:52
rss status
32 (unknown)
rss found date
2024-02-08 13:47:03
rss size orig
22295
rss items
3
rss spam phrases
0
rss detected language
1 (English)
inbefore feed id
-
inbefore status
0 (new)
sitemap path
sitemap status
30 (processing completed, results pushed to table crawler_sitemaps.ext_domain_sitemap_lists)
sitemap review version
1
sitemap urls count
4
sitemap urls adult
0
sitemap filtered products
0
sitemap filtered videos
0
sitemap found date
2024-02-08 00:49:46
sitemap process date
2024-10-18 02:39:04
sitemap first import date
-
sitemap last import date
-